Panadol ActiFast 500mg Soluble Tablets
*Company:
Haleon Ireland LimitedStatus:
UpdatedLegal Category:
Supply through general saleActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 19 December 2024
File name
Panadol Actifast soluble tablets - Clean.pdf
Reasons for updating
- Change to section 6 - manufacturer
Free text change information supplied by the pharmaceutical company
Change from GSK Dungarvan to Haleon Dungarvan
Updated on 26 June 2023
File name
ie-spc-panadolactifastsol-special population update to SPC-clean-approved M1-230118SKDJ.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Update to include posology for special populations and warning for hepatotoxicity
Updated on 03 April 2023
File name
ie-spc-Panadol Actifast 500mg Soluble Tablets-MAH name change-clean-230322SKDJ.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Change in MAH from GSK to Haleon Ireland Limted
Updated on 03 April 2023
File name
ie-mockup-Panadol Actifast Sol-MAH name change-leaflet-230322SKDJ.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
Free text change information supplied by the pharmaceutical company
Change MAH from GSK to Haleon Ireland Limited
Updated on 21 September 2022
File name
ie-spc-panadolactifastsol-PRAC update-clean-220511SKDJ.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Supply through general sale
Updated on 20 September 2022
File name
ie-mockup-panadol actifast soluble-proposed-220511SKDJ.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
Updated on 29 May 2020
File name
ie-mockup-pl-panadolactifastsol-200320em-proposed.pdf
Reasons for updating
- Improved presentation of PIL
Updated on 19 December 2019
File name
ie-pl-actifastsol 39-14-clean.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - dose and frequency
- Change to section 3 - how to take/use
- Change to section 4 - how to report a side effect
Updated on 18 December 2019
File name
ie-spc-panadolactifastsol-clean.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.6 - Pregnancy and lactation
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Supply through general sale
Updated on 12 August 2019
File name
ie-mockup-pl-panadolactifastsol-pd-190603em.pdf
Reasons for updating
- New PIL for new product
Updated on 12 August 2019
File name
ie-spc-panadolactifastsol-clean-name-190603em-with PRAC.pdf
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
change in product name